Investor Newsletter

Issue 09 2020

MicroPort™

Two MicroPort® EP Diagnostic Catheters Approved in Australia

Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP") has recently obtained registration approval from Australia's Therapeutic Goods Administration (TGA) for its proprietary EasyFinder™ Fixed Curve Diagnostic Catheter and EasyFinder™ Steerable Curve Diagnostic Catheter.

Severe arrhythmia is the main cause of sudden cardiac death. MicroPort® EP has developed a line of proprietary products, such as the Ablation Catheter, Diagnostic Catheter, 3D EP Navigation System, RF Generator, and Irrigation Pump, for use in radiofrequency ablation among patients with arrhythmias. Of these products, the Diagnostic Catheter is mainly used in the diagnosis of arrhythmia. The EasyFinder™ Fixed and Steerable Curve Diagnostic Catheter can be used in conjunction with a polygraph or a stimulator to navigate electrocardiosignals during EP examinations and surgeries, while the EasyFinder™ Steerable Curve Diagnostic Catheter allows for the mapping of multiple body parts, which helps to improve procedural efficiency and reduce radiation exposure to surgeons and patients.

Earlier in the first half of this year, a series of products developed by MicroPort® EP, including the FireMagic™ Cardiac RF Ablation Catheter, FireMagic™ 3D Irrigated Ablation Catheter, EasyLoop™ Circular Mapping Catheter, Columbus™ External Reference Patch and FORLNK™ Cables, have successfully entered the Australian market. The two Diagnostic Catheters, now TGA approved, will better complement the RF Ablation Catheter and other products already on the market, providing an integrated cardiac-electrophysiological medical solution for local patients and physicians, while laying a solid foundation for the further expansion of MicroPort® EP into the Oceania market.





Multiple MicroPort® EP Catheters and Devices Approved in Uzbekistan

Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP") has recently obtained registration approval by the Uzbekistan Ministry of Health (MOH) for its proprietary catheters and other devices, marking its first entry into Uzbek market.

Arrhythmia is a common cardiovascular disease, and severe arrhythmia is the main cause of sudden cardiac death. Radiofrequency ablation surgery is one of the most important non-pharmacological treatments for arrhythmias. The approved catheters and devices, including FireMagic™ Cardiac RF Ablation Catheter, FireMagic™ 3D Irrigated Ablation Catheter, EasyFinder™ Fixed Curve Diagnostic Catheter, EasyFinder™ Steerable Curve Diagnostic Catheter, EasyLoop™ Circular Mapping Catheter, OptimAblate™ Tubing Set, Columbus™ External Reference Patch, FORLNK™ Cables, Columbus™ 3D EP Navigation System, Columbus™ Cardiac Electrophysiology Stimulator, OptimAblate™ Cardiac RF Generator and OptimAblate™ Irrigation Pump, are intended for the rapid diagnosis and effective treatment of arrhythmias.

As a major hub of the "Belt and Road" initiative, Uzbekistan has a population of more than 30 million people. Statistics show that approximately 1.5 million cases of acute or chronic cardiovascular disease are reported in Uzbekistan annually, with almost 20% of the population aged between 40 and 64 considered at risk. Cardiovascular disease is the leading cause of death, accounting for more than 60% of all deaths. The introduction of MicroPort® EP products into the Uzbek market is expected to provide more efficient and convenient treatment options for local patients suffering from arrhythmias. In the future, MicroPort® EP will continue to respond actively to the "Belt and Road" health partnership initiative by building on its autonomous innovation and expanding into overseas markets. In doing so, it aims to support medical personnel in countries along the "Belt and Road" region to master and apply more advanced treatment methods for the benefit of more patients worldwide.



First Implant of Firehawk™ Stent Successfully Completed in Oman

On September 10, 2020, the first implant of the Firehawk™ Rapamycin Target Eluting Coronary Stent System ("Firehawk™") developed by Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") was completed successfully in Muscat, Oman.

The surgery was performed at Al-Hayat Hospital by renowned Omani cardiologist Prof. Mohammed El-Deeb, who successfully implanted a 3.5 x 23mm Firehawk™ stent. "I am pleased to complete the first implant of Firehawk™ after it entered the Omani market," said Prof. El-Deeb. "The Firehawk™ stent has excellent crossability, visibility and radial strength."

Firehawk™ has been introduced into more than 2,200 hospitals in nearly 40 countries covering key markets across Asia-Pacific, Europe and South America, and is globally recognized by clinical experts for its innovation. The successful implant marks the official entry of Firehawk™ into the Omani market, a milestone for MicroPort® in Oman and across the Middle East. MicroPort® is committed to providing high-quality and innovative medical devices and integrated solutions to meet the clinical needs of patients and healthcare experts. As Firehawk™ continues to enter new markets, it further strengthens MicroPort®'s cooperation with overseas experts and that ability to provide technologies in the overseas market that benefit patients worldwide.





MicroPort® NeuroTech Obtains Approval for NUMEN™ Coil Embolization System in China

MicroPort® NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech") recently obtained registration certificates for NUMEN™ Coil Embolization System and NUMEN FR™ Detachment System from National Medical Products Administration of China (NMPA). The devices can be used in the embolization procedure to treat intracranial aneurysm. The approval for the devices signified further improvements in Microport® NeuroTech's neurovascular device line.

Mr. Roy Xie, president of MicroPort® NeuroTech said, "The coil embolization is a particularly important therapeutic solution for the treatment of intracranial aneurysm. The marketing of NUMEN™ Coil Embolization System will mark a step closer to making Microport® NeuroTech a provider of complete solutions to stroke so as to benefit more patients in the future.

MicroPort

Shanghai MicroPort® Medical Wins Award of Science and Technology Innovation of Outstanding Fulfillment of Corporate Social Responsibility in Shanghai

On September 7, 2020, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") won the Award of Science and Technology Innovation at the Press Conference on 2020 Shanghai Corporate Social Responsibility Report organized by Shanghai Federation of Economic Organizations for its outstanding achievement in the science and technology innovation. Leanne Li, Board Secretary & VP of Securities Affairs, received the award on behalf of the company and reported on the highlights of MicroPort®'s social responsibility performance for the Year 2019.

The Award of Science and Technology Innovation demonstrates that MicroPort®'s outstanding performance in innovation has once again been highly recognized by the society. MicroPort®, drived by innovation with needs of patients and doctors as orientation, will always provide trustworthy and universal access to state-of-the-art solutions of prolonging and reshaping lives.

MicroPort

MicroPort® (00853.HK) Included in HSMI and HSLMI Indexes and Officially Eligible for Trading through Shanghai-HK Stock Connect

Effective on Monday, September 7, 2020, MicroPort Scientific Corporation (MicroPort®, 00853.HK) has been included in the Hang Seng Composite MidCap Index ("HSMI") and the Hang Seng Composite LargeCap & MidCap Index ("HSLMI") managed by Hang Seng Indexes Company Limited. Meanwhile, a recent announcement by the Shanghai Stock Exchange ("SSE"), which introduced updates to the list of stocks eligible for trading through Hong Kong Stock Connect, marks the official inclusion of MicroPort® in the Hong Kong Stock Connect list on September 7, 2020.

The Hang Seng Composite Index ("HSCI") offers a comprehensive Hong Kong market benchmark that covers about the top 95th percentile of the total market capitalization of companies listed on the Main Board of the Stock Exchange of Hong Kong ("SEHK"). To be eligible for inclusion in the HSCI index, public companies are required to meet a wide range of requirements, such as market capitalization and share liquidity, as set out in its Index Methodology.

With Hong Kong Stock Connect, investors in Mainland China entrust securities companies based in the Mainland to trade stocks listed on SEHK through a securities trading service company established by the SSE. Stocks eligible for trading through Hong Kong Stock Connect are the constituent stocks of HSLI and HSMI—the large-cap and mid-cap indexes of HSCI—as well as the "A+H shares" that are listed on both SEHK and SSE. Currently, 264 stocks are eligible for trading through Hong Kong Stock Connect, accounting for about 80% of the total market capitalization and trading volume of SEHK listed stocks.

MicroPort® has been eligible for trading through Shenzhen-Hong Kong Stock Connect since 2017. The Company's inclusion in the HSMI and HSLMI indexes as well as the Shanghai-Hong Kong Stock Connect program, back-to-back with its earlier listing in the MSCI Hong Kong Index, is a reflection of investors' recognition and confidence in the development prospects and market capitalization outlooks of MicroPort®. In the meantime, it also opens up new channels for mainland investors to invest in the Company's equity shares.

恒生指數
HANG SENG INDEXES

Investor Newsletter

Issue 09 2020

MicroPort™

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com